Clinical Cancer Research, Vol 3, Issue 1 135-142, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Basic fibroblast growth factor confers growth inhibition and mitogen-activated protein kinase activation in human breast cancer cells

E Fenig, R Wieder, S Paglin, H Wang, R Persaud, A Haimovitz-Friedman, Z Fuks and J Yahalom
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

The effect of basic fibroblast growth factor (bFGF) on human breast cancer cells was studied in vitro. Exposure to bFGF resulted in significant growth inhibition, decreased DNA synthesis, and accumulation of cells in G0-G1. The IC50 for growth inhibition in MCF-7 cells was 50 pg/ml, and it was abrogated by neutralizing antibodies against bFGF. Inhibition of growth by bFGF was predominant over the growth stimulatory effects of 17beta-estradiol, insulin, or epidermal growth factor. Binding and cross-linking studies of 125I-labeled bFGF in intact MCF-7 cells demonstrated 5.2 x 10(3) saturable bFGF binding sites per cell, a dissociation constant of 57 pm, and a Mr 142,000 (125)I-labeled bFGF cross-linked protein. Stimulation of MCF-7 cells with bFGF at concentrations which effected growth inhibition also resulted in activation of p42(mapk) (ERK2) and p44(mapk) (ERK1) mitogen-activated protein kinases. These data demonstrate that whereas bFGF inhibits the growth of several breast cancer cell lines, it concomitantly activates ERK1 and ERK2, generally considered to signal mitogenic rather than growth inhibitory responses. Whether there is association between these phenomena remains unknown.

This article has been cited by other articles:

				A. Kondo, N. Hirayama, Y. Sugito, M. Shono, T. Tanaka, and N. Kitamura Coupling of Grb2 to Gab1 Mediates Hepatocyte Growth Factor-induced High Intensity ERK Signal Required for Inhibition of HepG2 Hepatoma Cell Proliferation J. Biol. Chem., January 18, 2008; 283(3): 1428 - 1436. [Abstract] [Full Text] [PDF]

				E. Fitzpatrick, S. McBride, J. Yavelow, S. Najmi, P. Zanzucchi, and R. Wieder Microfluidic Techniques for Single-Cell Protein Expression Analysis Clin. Chem., June 1, 2006; 52(6): 1080 - 1088. [Abstract] [Full Text] [PDF]

				S. Najmi, R. Korah, R. Chandra, M. Abdellatif, and R. Wieder Flavopiridol Blocks Integrin-Mediated Survival in Dormant Breast Cancer Cells Clin. Cancer Res., March 1, 2005; 11(5): 2038 - 2046. [Abstract] [Full Text] [PDF]

				S. Song, B. Yu, Y. Wei, M. G. Wientjes, and J. L.-S. Au Low-Dose Suramin Enhanced Paclitaxel Activity in Chemotherapy-Naive and Paclitaxel-Pretreated Human Breast Xenograft Tumors Clin. Cancer Res., September 15, 2004; 10(18): 6058 - 6065. [Abstract] [Full Text] [PDF]

				R. Korah, M. Boots, and R. Wieder Integrin {alpha}5{beta}1 Promotes Survival of Growth-Arrested Breast Cancer Cells: An in Vitro Paradigm for Breast Cancer Dormancy in Bone Marrow Cancer Res., July 1, 2004; 64(13): 4514 - 4522. [Abstract] [Full Text] [PDF]

				F. Hollande, E. M. Blanc, J. P. Bali, R. H. Whitehead, A. Pelegrin, G. S. Baldwin, and A. Choquet HGF regulates tight junctions in new nontumorigenic gastric epithelial cell line Am J Physiol Gastrointest Liver Physiol, May 1, 2001; 280(5): G910 - G921. [Abstract] [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				Q. Wang, W. Yang, M. S. Uytingco, S. Christakos, and R. Wieder 1,25-Dihydroxyvitamin D3 and All-trans-Retinoic Acid Sensitize Breast Cancer Cells to Chemotherapy-induced Cell Death Cancer Res., April 1, 2000; 60(7): 2040 - 2048. [Abstract] [Full Text]

				M. E. Burow, C. B. Weldon, B. M. Collins-Burow, N. Ramsey, A. McKee, A. Klippel, J. A. McLachlan, S. Clejan, and B. S. Beckman Cross-talk between Phosphatidylinositol 3-Kinase and Sphingomyelinase Pathways as a Mechanism for Cell Survival/Death Decisions J. Biol. Chem., March 24, 2000; 275(13): 9628 - 9635. [Abstract] [Full Text] [PDF]

				R. M. Korah, V. Sysounthone, Y. Golowa, and R. Wieder Basic Fibroblast Growth Factor Confers a Less Malignant Phenotype in MDA-MB-231 Human Breast Cancer Cells Cancer Res., February 1, 2000; 60(3): 733 - 740. [Abstract] [Full Text]